Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting

Roche has hosted a virtual event on Monday, 14^th June 2021.

Agenda:

JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with spinal muscular atrophy (SMA) receiving treatment with risdiplam
RAINBOWFISH: A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA)
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
Q&A
Kathryn Wagner, M.D. Ph.D., Vice President of Neuromuscular Disorders Clinical Development
Paulo Fontoura, M.D. Ph.D., Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases Clinical Development
Simona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
Kavita Patel, Lifecycle Leader SMA, Global Product Strategy

Please register to access the webcast*

First Name

Last name

Corporate Email

Company Name

Job Role

Country

* Mandatory

Please come back 30 minutes before the webcast start date and fill in the registration form.